Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | - | - |
INDMoney rank | 2/8 | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 9 Years | 7 Years | ||
Fund Size | 1282 Cr | 5728 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.62% | 1.06% | ||
Exit Load | 0.25% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 37 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.17%) Apollo Hospitals Enterprise Ltd (7.19%) Cipla Ltd (5.76%) Divi's Laboratories Ltd (5.58%) Aurobindo Pharma Ltd (5.44%) | Sun Pharmaceuticals Industries Ltd (12.23%) Divi's Laboratories Ltd (8.95%) Dr Reddy's Laboratories Ltd (8.92%) Cipla Ltd (7.75%) Aurobindo Pharma Ltd (6.06%) | ||
No of Sectors | 3 | 3 | ||
Top 3 Sectors | Health (96.43%) Basic Materials (2.54%) Financial Services (1.04%) | Health (96.08%) Basic Materials (2.8%) Financial Services (1.12%) | ||
Equity % | 92.32% | 96.45% | ||
Debt % | - | - | ||
P/E | 37.45 | 31.57 | ||
P/B | 5.54 | 4.13 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.01% | 2.05% | ||
3-Month Return | 8.99% | 13.85% | ||
6-Month Return | 1.63% | 5.38% | ||
1-Year Return | 13.18% | 19.57% | ||
3-Year Return | 25.51% | 29.82% | ||
5-Year Return | 23.79% | 25.63% |
Sharpe | 1.18 | 1.43 | ||
Alpha | 4.1 | 3.56 | ||
Beta | 0.95 | 0.94 | ||
Standard Deviation | 15.96 | 15.37 | ||
Information Ratio | 1.33 | 1.04 |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Dharmesh Kakkad |